Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Division of Hematology and Oncology, Department of Internal Medicine, Saint Louis University, St Louis, MO.
Stacey M
SM
Parker
Mustafa A
MA
Hyder
Mark J
MJ
Fesler
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000150:complications* / Q000209:etiology*; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride
Hepatic; Immunochemotherapy; Liver